Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Prostaglandin transporter PGT as a new pharmacological target in the prevention of inflammatory cytokine-induced injury in renal proximal tubular HK-2 cells

  • Yago Ibáñez, Julia
  • Muñoz Moreno, Laura|||0000-0002-2322-8986
  • Gallego Tamayo, Beatriz|||0000-0002-7240-7200
  • Lucio Cazaña, Francisco Javier de|||0000-0001-9249-8501
  • Fernández Martínez, Ana Belén
Aims: Inflammatory cytokines contribute to proximal tubular cell (PTC) injury leading to the deterioration of renal function and acute kidney injury (AKI) development. They also stimulate cyclo oxygenase-2 (COX-2)- dependent production and release to the extracellular medium of prostaglandin E2 (PGE2), a mediator of PTC injury. However, in several settings PGE2 re-uptake by prostaglandin transporter (PGT) is critical for PGE2- mediated PTC injury. Here we investigated several deleterious effects of pro-inflammatory cytokines in PTC and their prevention by PGT targeting. Main methods: In human kidney-2 (HK-2) PTC exposed to an inflammatory cytokine cocktail, consisting of interleukins (IL) IL-1α, IL-1β and IL-2, tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), were determined the changes in several parameters related to PTC injury, their dependency on PGE2 (through modulation by antagonists of PGE2 receptors) and the preventive effect of PGT inhibitor bromosulfophthalein. Key findings: The cytokine cocktail induced a COX-2-dependent increase in intracellular PGE2 (iPGE2) and cell death, together to a decrease in cell number and cell proliferation. There was also loss of adherent cells to collagen IV, changes in actin cytoskeleton and loss of monolayer integrity, together to an increase in paracellular permeability. All the changes were sensitive to antagonist of PGE2 receptors AH6809 and were fully prevented by bromosulfophthalein. Significance: These results indicate that PGT-, iPGE2-dependent mechanisms mediate inflammatory cytokineinduced HK-2 cell injury and suggest that treatment with PGT inhibitors might help to prevent AKI induced by sepsis, renal ischemia/reperfusion and other pathological conditions in which inflammatory cytokines contribute to PTC damage., Universidad de Alcalá, Comunidad de Madrid
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Diabetic individuals with COVID-19 exhibit reduced efficacy of gliptins in inhibiting dipeptidyl peptidase 4 (DPP4). A suggested explanation for increased COVID-19 susceptibility in patients with type 2 diabetes mellitus (T2DM)

  • Mora Rodríguez, José María|||0000-0003-0831-8067
  • Sánchez Gómez, Belén|||0000-0003-0971-1522
  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Díaz Yuste, Alba
  • Ballesteros Gonzalez, Ruben
  • Arrieta Blanco, Francisco Jesús
  • Sebastián Martín, Alba|||0000-0001-7354-8964
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
Aims: Dipeptidyl peptidase 4 (DPP4) has been proposed as a coreceptor for SARS-CoV-2 cellular entry. Considering that type 2 diabetes mellitus (T2DM) has been identified as the most important risk factor for SARS-CoV-2, and that gliptins (DPP4 inhibitors) are a prescribed diabetic treatment, this study aims to unravel the impact of DPP4 in the intersection of T2DM/COVID-19. Materials and methods: We analyzed 189 serum human samples, divided into six clinical groups (controls, T2DM, T2DM + gliptins, COVID-19, COVID-19 + T2DM, and COVID-19 + T2DM + gliptins), measuring DPP4 protein concentration and activity by Western blot, ELISA, and commercial activity kits. The obtained results were verified in Huh-7 cellular models. Key findings: Both DPP4 concentration and activity were decreased in COVID-19 patients, and as in T2DM patients, compared to controls. Despite these lower levels, the ratio of DPP4 activity/concentration in COVID-19 sera was the highest (0.782 ± 0.289 ?U/ng vs. 0.547 ± 0.050 ?U/ng in controls, p < 0.0001), suggesting a compensating mechanism in these patients. Supernatants of Huh-7 cells incubated with COVID-19 serum showed a consistent and significantly lower DPP4 concentration and activity. Furthermore, COVID-19 + T2DM + gliptins patients showed a higher serum DPP4 concentration and activity than T2DM + gliptin subjects (p < 0.05), indicating that sera from COVID-19 convalescents interfere with gliptins. Significance: Either SARS-CoV-2 or some metabolites present in the sera of COVID-19-convalescent patients interact with soluble DPP4 or even gliptins themselves since the inhibitory effect of gliptins on DPP4 activity is being prevented. The interactions between DPP4, gliptins, and SARS-CoV-2 should be further elucidated to reveal the mechanism of action for these interesting observations., Instituto de Salud Carlos III, Comunidad de Madrid, Universidad de Alcalá, Fundación Tatiana Pérez de Guzmán el Bueno